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Background: Heat shock proteins (HSPs), including mainly HSP110, HSP90, HSP70, HSP60 and small HSP families,
are evolutionary conserved proteins involved in various cellular processes. Abnormal expression of HSPs has been
detected in several tumor types, which indicates that specific HSPs have different prognostic significance for
different tumors. In the current studies, the expression profiling of HSPs in human low-grade glioma tissues (HGTs)
were investigated using a sensitive, accurate SILAC (stable isotope labeling with amino acids in cell culture)-based
quantitative proteomic strategy.
Results: The five HSP family members were detected and quantified in both HGTs and autologous para-cancerous
brain tissues (PBTs) by the SILAC-based mass spectrometry (MS) simultaneously. HSP90 AB1, HSP A5(70 KDa), and
especially HSP27 were significantly downregulated in HGTs, whereas the expression level of HSPA9 (70 KDa) was
little higher in HGTs than that in PBTs. It was noted that the downregulation ratio of HSP27 was 0.48-fold in HGTs
versus PBTs, which was further validated by results from RT-PCR, western blotting and immunohistochemistry.
Furthermore, we detected HSP27 expression changes along with cell growth under heat shock treatment in glioma
H4 cells.
Conclusion: The SILAC-MS technique is an applicable and efficient novel method, with a high-throughput manner,
to quantitatively compare the relative expression level of HSPs in brain tumors. Different HSP family members have
specific protein expression levels in human low-grade glioma discovered by SILAC-MS analysis. HSP27 expression
was obviously downregulated in HGTs versus PBTs, and it exhibited temporal and spatial variation under heat shock
treatment (43°C/0-3 h) in vitro. HSP27’s rapid upregulation was probably correlated with the temporary resistance
to heat shock in order to maintain the survival of human glioma cells.
Background
Heat shock proteins (HSPs) are evolutionary conserved
proteins involved in various cellular processes. Accord-
ing to their different molecular weights, structure and
functions, HSPs contain major five groups, including the
HSP110/HSP100, HSP90, HSP70, HSP60 and small HSP
families [1]. The expressions of HSPs are induced under
the existence from oxidative stresses, heavy metals,
osmotic stresses, metabolic poisons, viral/microbial
infections and other external stresses [1,2]. HSPs have
multiple intracellular functions, including protein cha-
peroning [3], signal transduction, modulation of
immune response [4], differentiation and proliferation
[5], as well as regulation of apoptosis [6]. In tumor cells,
HSPs are also involved in the resistance to therapeutic
agents [7,8].
However, the amino acids and biological functions dif-
fer among individual HSP family and different members
[3]. For example, heat shock protein 27 (HSP27), also
called HSP B1, belongs to the small HSP family with a
27-KDa molecular weight, which is found to express
from prokaryotes to mammals [9]. HSP27 has potential
to interact with several proteins [1,9], including as a
multiple inhibitor of apoptosis [10-12]. HSP27 can
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any medium, provided the original work is properly cited.negatively regulate cell death by interacting with cyto-
chrome c [13], and it can also activate protein kinase B
and Akt, which inhibit cell death by phosphorylating
and inactivating procaspase-9 [14].
Previous studies have indicated that HSP27 expression
is implicated in prognosis in many cancers, however it
has a different prognostic indication for different types
of tumors. The prognosis is poor when HSP27 expresses
in ovarian [15], gastric [16], liver [17] and prostate can-
cer [18], as well as osteosarcoma [19]. Oppositely,
HSP27 expression suggests a good prognosis in endome-
trial adenocarcinoma, oesophageal cancer and malignant
fibrous histiocytoma [20]. By now, most of studies on
HSP expression in brain tumor tissues have been
obtained from conventional methods, such as immuno-
histochemistry [21-23] or two-demensional gel eletro-
phoresis [24]. Currently, novel proteomic techniques,
especially the stable isotope labeling with amino acids in
cell culture (SILAC)-based quantitative proteomics [25],
offer possibility of systematically investigating the
expression profiling of different HSP members in glioma
in terms of quantitative view. Because the SILAC-based
quantitative proteomics is a powerful tool in distinguish-
ing the isoform-specific expression profiling in tissues,
by which in vivo tagging of an isotope-labeling amino
acid in proteins assists quantitative comparisons for dif-
ferentially expressed proteins in different pathological
tissues [26-28].
In the current report, by using this novel proteomic
approach, we investigated the differentital expression
profiling of HSPs between human glioma tissues
(HGTs) and autologous para-cancerous brain tissues
(PBTs). Besides, we further focused on the expression
variations of HSP27 by heat shock in a glioma-derived
cell line H4, as well as analyzed the relationship between
HSP27 expression and cell growth. These findings pre-
sented the first quantitative proteomic analysis on HSPs
in HGTs. The lower expression of HSP27 in glioma tis-
sues is probably associated with cell differentiation in
human glioma development, and the rapidly upregula-
tion of HSP27 against heat shock in vitro m a yh a v ea
temporary potential to increase survival ability of glioma
cells.
Results
Labeling course for incorporation of Leu-d3 in H4 cells
A time course was performed to detect the labeling effi-
ciency which was required for cells to incorporate the
deuterated-leucine (Leu-d3) fully into all proteins. As
described in our previous papers [26,29,30], b-actin was
usually chosen to detect the labeling efficiency. For
example, we detected the incorporation ratio of Leu-d3
labeling in a representative Leu-containing peptide
(SYELPDGQVITIGNER) of b-actin. Because the normal
L-leucine (Leu-d0) was gradually replaced with the Leu-
d3 into b-actin during cell growth, the ratio of peptide
intensity of the Leu-d3-labeling peptide versus Leu-d0-
containing peptide was steadily increased (Figure 1). A
larger incorporation of Leu-d3 was observed at later
time points with full incorporation after the 5th cell pas-
sage, and the incorporation rate of Leu-d3 exceeded
97%. Thus the labeling H4 cells were harvested at least
after five cell passages to extract proteins for the follow-
ing SILAC and mass spectrometric analysis.
Protein expression profiling of HSPs in human glioma
tissues
Because the original SILAC approach is directly applied
in cell system, we have expanded it for tissue proteome
quantification indirectly based on Leu-d3-labeling pro-
teins from a cultured glioma-derived cell line H4 as
internal standards [27]. Corresponding to the low-grade
glioma tissues in our present study, H4 is a neuroglioma
cell line derived from a low-grade malignant glioma
[31-33] to take as an internal standard for protein rela-
tive quantification in MS [27], which was proved to
express all of HSP proteins those were identified in
human glioma tissues. The principle for protein quanti-
fication and comparison between two states of tissues
by SILAC-MS had been portrayed in our previous
papers [26-28].
In order to normalize the internal standard for com-
parison, we first compared the expression level of
housekeeping protein b-actin in HGTs and PBTs. As
shown in the Table 1, the SILAC ratio was close to 1.00
either in HGTs or in PBTs, which suggested that it
expressed with similar levels between these two states of
brain tissues. This was also indicated that the total pro-
tein mixture from labeling H4 cells and HGTs was
equal to that quantity mixed from labeling H4 cells and
PBTs, and there was no need for additional normaliza-
tion to compare.
The relative expression levels of HSPs were summar-
ized as Table 1 based on the change-ratio of SILAC
Ratio1 versus SILAC Ratio 2 (Ratio1/Ratio2), which
was obtained from the average of two biological repli-
cate experiments. The average relative standard devia-
tion (RSD) of the SILAC ratio was 0.16 for all
quantified HSP proteins. Based on our quantitative cri-
teria established [26-30], in our present study, the cut-
off selection of change ratio is set 2-fold RSD (0.32) as
the threshold. In other words, we assigned the ratio of
up-regulation over 1.32 and the down-regulation below
0.68 for both altered proteins. Therefore, the HSP27
(IPI00025512), HSP A5 (IPI00003362) and HSP90AB1
(IPI00334775) respectively had 0.48, 0.58 and 0.64-fold
downregulation in HGTs compared with that in
PBTs. And HSPA9 (IPI00007765) was increased with
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Page 2 of 121.44-fold in HGTs, while the other HSP members,
listed in the Table 1, exhibited no significant differ-
ences between HGTs and PBTs. The representative
pairs of isotope labeling peptides for quantification
were illustrated as Figure 2 and 3, respectively from
the control b-actin, a down-regulated protein HSP27
and an unchanged HSPA8.
Expression validation of HSP27 in human glioma tissues
In order to validate the expression level of HSP27 by the
quantitative proteomic analysis, the expression status of
HSP27 in mRNA and protein levels were compared by a
semi-quantitative RT-PCR and western blotting between
glioma and para-cancerous brain tissues. As shown in
the Figure 4, compared with the expression level in
PBTs, HSP27 was decreased in glioma tissues both at
mRNA (Figure 4A) and protein levels (Figure 4B). Three
cases of HGTs and PBTs were performed repeatedly,
and same results were obtained.
We further analyzed the expression and distribution of
HSP27 between two types of brain tissues by immuno-
histochemistry (IHC). As shown in Figure 5, the para-
cancerous brain tissues had intensive HSP27 immunor-
eactivity in neuroplasm of the neuronal somata and
proximal processes (Figure 5-C2). While under same
conditions, the relative expression level of HSP27 was
much lower in glioma tissues (Figure 5-D2). All these
data were consistent with the above quantitative proteo-
mic results.
The correlation between the expression variation of
HSP27 and cell growth under heat shock treatment
The previous reports indicated that HSP27 overexpres-
sion in vivo exhibited neuroprotective properties by
HSP27-mediated inhibition of apoptosis in neuronal
cells [34]. Based on these reports and our current data,
we speculated whether the lower expression of HSP27
in glioma could regulate cell survival via its anti-
Figure 1 Incorporation of Leu-d3 in b-actin at different passages of H4 cells. A-D represented samples respectively from 1, 3, 5 and
7 passages of labeled H4 cells. The represented pairs of peptides “SYELPDGQVITIGNER” from b-actin were analyzed at different time points
by ESI-TOF/MS. The intensity ratio of pairs of isotope peaks (m/z, 897/895) was respectively about 65.78%, 94.92%, 97.23% and 97.67%.
After seven passages, the incorporation of Leu-d3 was exceed 97.5%, which indicated that the labeling was complete.
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relations of its expression with cell growth under heat
shock in H4 cells. As presented in Figure 6, the expres-
sion of HSP27 exhibited temporal and spatial variations
under heat shock treatment (43°C)for 0-3 h. Compared
with the untreated control cells, HSP27 expression was
increased about 3.83 and 5.36-fold at 30 min and 1 h
after heat shock, then gradually jumped back near to the
background level at the time point of 2 h and 3 h,
respectively with 2.3 and 1.12-fold expression level ver-
sus the control.
In order to investigate whether there were some rela-
tionships between HSP27 expression and cell growth in
vitro under heat shock, cell growth was detected by 3-
(4,5-dimethylthiazol- z-y1)-2,5-diphenyltetrazolium bro-
mide (MTT). It was noticed that cell proliferation ability
under heat shock at the time point of 30 min(OD595 nm,
0.57 ± 0.03, n = 18) was almost similar with that at 1 h
(OD595 nm,0 . 5 7±0 . 0 4 ,n=1 8 ) ,w h i c hi n d i c a t e dt h a ta
rapid increase of HSP27 expression in H4 cells can
exhibit resistance to a transitory external stress
(hyperthermia). The cell survival number was changed
little at the time point of 2 h (OD595 nm,0 . 4 8±0 . 0 3 ,n
= 18) and 3 h (OD595 nm, 0.47 ± 0.03, n = 18) treatment.
However, at each treatment period during 0.5-1 h and
2-3 h, compared with control group (OD595 nm,0 . 6 3±
0.05, n = 18), cell growth had significantly decreased
(p < 0.01) in these two groups. Therefore, under heat
shock treatment within 0-3 h, cell survival rate was gra-
diently diminished corresponding to the variation of
HSP27 expression in H4 cells (Figure 7).
Discussion
The hotspot chaperone molecules – heat shock proteins,
have been disclosed to be tightly associated with the brain
tumors, and the expression variations of HSPs imply the
progressive staging and prognosis of glioma [20-24,35],
which provides a novel attempt to develop the utility of a
specific HSP as the diagnotic target and therapeutic inter-
vention [24,35]. Therefore, in current study, we mainly








Protein name IPI no.(a) HGTs (c) PBTs (d) Ratio1 Ratio2 HGTs (c) PBTs (d) Change-Ratio(g)
(ratio1/ratio2)
HSP110/100 family
HSP H1(105 KD) IPI00218993 77(8) 140(10) 0.61 ± 0.02 (2) 0.82 ± 0 (1) 2.7 1.6 0.74
HSP90 family
HSP90 AB1 IPI00334775 428(18) 179(10) 0.29 ± 0.17 (6) 0.45 ± 0.26 (3) 8.7 4.8 0.64
HSP90 AA1 IPI00382470 82(14) 109(11) 0.80 ± 0.43 (4) 0.75 ± 0.52 (2) 6 3 1.07
HSP70 family
HSP A8(71 KD) IPI00003865 486(16) 360(17) 0.52 ± 0.09 (8) 0.55 ± 0.1(3) 17 5 0.95
HSP A9(70 KD) IPI00007765 401(16) 127(5) 0.49 ± 0.09 (5) 0.34 ± 0 (1) 9.6 2.2 1.44
HSP A5(70 KD) IPI00003362 508 (15) 99(8) 0.33 ± 0.15 (7) 0.57 ± 0.28 (2) 14 3.2 0.58
HSP60 family
HSP D1(60 KD) IPI00472102 67(9) 419(20) 0.57 ± 0.08 (3) 0.52 ± 0.27(4) 33 18 1.10
Small HSP family
HSP B1(27 KD) IPI00025512 159(12) 138 (10) 0.29 ± 0.12 (4) 0.61 ± 0.32 (3) 8.2 7 0.48
Control protein
b-actin IPI00021439 687(31) 643(39) 1.03 ± 0.02 (4) 0.98 ± 0.03 (4) 12 12 1.05
(a) IPI (International Protein Index) no. is the protein accession number, which was derived from the EMBL-EBI database.
(b) ‘MOWSE’ is derived from molecular weight search, and it is a method for the identification of proteins from the molecular masses of peptides created by
proteolytic digestion and measured by MS.
(c) The protein mixture from HGTs and Leu-d3labeling H4 cells; HGTs: human glioma tissues.
(d) The protein mixture from PBTs and Leu-d3labeling H4 cells; PBTs: para-cancerous brain tissues.
(e) SILAC ratio1 (HGTs/H4) and SILAC ratio2 (PBTs/H4): the peak intensity ratio of Leu-d0-labeling peptides from HGTs or PBTs versus that of Leu-d3-labeling
peptides from H4 cells, which was quantified using Analyst QS software.
(f) The number of unique Leu-containing peptides of one protein to calculate SILAC ratio1 and SILAC ratio2.
(g) The Change-Ratio between two tissues (SILAC Ratio1/SILAC Ratio2).
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expression differences of HSPs between human low-grade
glioma tissues and the autologous PBTs. HSP27 was iden-
tified to have lower expression levels in HGTs, which was
validated not only by RT-PCR, western blot and IHC data,
but also by previous other’s reports [21-23], including in
Hermission’s paper [23].
More importantly, this SILAC-based quantitative pro-
teomic method provides several new information of
HSP family proteins in HGTs by investigating protein
expression profiling. Firstly, the SILAC-MS technique
can precisely take ‘in-spectra’quantitative measurement
of expressing profiles of HSPs in different states with a
high-throughput manner according to the ratio of
Figure 2 One pair of isotope peptides (m/z, 582/581) “EITALAPSTMK” of b-actin was chosen to be an internal standard to validate the
mixture ratio. (A) showed the peak intensity of the isotope-labeling peptides from the protein mixture containing human glioma tissues (HGTs)
and H4 cells. The SILAC ratio1 of HGTs versus labeled H4 cells was 1.03 ± 0.02. (B) represented the peak intensity of isotope-labeling peptides,
which came from the protein mixture from para-cancerous brain tissues (PBTs) and labeled H4 cells. The SILAC ratio2 of PBTs versus labeled H4
cells was 0.98 ± 0.03. Thus, the change ratio of b-actin in HGTs versus PBTs was 1.05, near 1:1, which indicated the expression of b-actin was
similar between the two tissues.
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principle has been delineated in detail and applied to
distinguish members belonging to a homologous protein
family in our recent studies [26-28]. The five main
members of HSP family were successfully identified and
quantified in HGTs simultaneously by the SILAC-aided
LC/MS-MS analysis, and their expression levels were
different in glioma. Especially, HSPA9 (70 KD) was
1.44-fold upregulation in HGTs, whereas the
HSP90AB1, HSPA5 and HSP27 all had lower expression
l e v e li nH G T st h a nt h a ti nP B T s .A l t h o u g hH S P A 9a n d
HSPA5 both belong to the same HSP70 family, HSPA9
is increased in HGTs, whereas HSPA5 is decreased. The
SILAC-MS method offers a sensitive and quick view of
expression characterization for HSP family than other
traditional protein-by-protein assessment, such as by the
relative strength of IHC/Western blot [21-23].
Secondly, we put emphasis on comparison with the
relative expression levels of HSPs between low-grade
HGTs (grade II) and their counterparts – autologous
PBTs by an accuratly quantitative proteomic method,
especially revealed the different expression changes of
HSP27 in the pathologic state, which provides valuble
clues in diagnosis and therapeutic intervention for
giloma. While Hermission et al. had just detected the
expression of HSPs in 12 human glioma cell lines by
Western blot and in glioma tissues by a qualitative IHC
[23]. It has been found that the expression of HSP27 in
human astrocytomas correlates with histologic grades
and tumor growth fractions. In the low-grade astrocyto-
mas, the HSP27 immunopositive rate was very low, but
t h ep o s i t i v er a t ew a ss i g n i f i c a n t l yh i g h e ri nt h eh i g h -
grade astrocytomas [21]. Our quantitative data on
HSP27 expression in low-grade glioma also supported
the previous results, which were obtained by a semi-
quantitative immunohistochemistry fashion.
Besides, we further investig a t e dt h a tt h ec o r r e l a t i o n s
between the expression variation of HSP27 and cell
growth in vitro under heat shock treatment. Transient
hyperthermia (43°C/0.5-2 hours) induced a rapidly
increased expression of HSP27 in H4 cells, especially it
accessed to the maximal with 5.36-fold expression by
heat treatment at 43°C for 1 h, whereas the cell growth
was almost not affected at the time point of 30 min and
1 h by heat shock. This indicated that the increased
expression of HSP27 by heat shock treatment in H4
cells can exhibit resistance to a transitory external stress,
hyperthermia-induced cell damage, to keep cell growth
and survival. However, in our current studies, the
mechanism against heat shock is not explored in detail
so far. For example, how did the expression variation of
HSP27 regulate cell survival signaling, and it cooperated
with other heat shock proteins, including HSPA9,
HSP90AB1 and HSPA5? And what were the expression
levels of the other three HSPs under the same heat
shock treatment? Future studies on these issues will
help us to understand the functional significance of
these HSPs in glioma.
Figure 3 The representative pairs of isotope labeling peptides to quantify HSP expression in glioma tissues.( A ) - ( B )w a st h ep e a k
intensity of isotope labeling peptide “SQIHDIVLVGGSTR” of HSPA8(71 KD) respectively from HGTs/H4 (A) and PBTs/H4(B) samples. A: the SILAC
ratio1 (HGTs/H4) of HSPA8 was 0.52 ± 0.9; B: the SILAC ratio2 (PBTs/H4) of HSPA8 was 0.55 ± 0.1. The change ratio (HGTs/PBTs) was 0.95 (0.52/
0.55) indicated HSPA8 was no significant change between glioma tissues and para-cancerous brain tissues. Similarly, the pairs of isotope labeling
peptide “LATQSNEITIPVTFESR“ of HSP27(HSPB1) from HGTs/H4 (C) and PBTs/H4(D) samples for quantitation, and the change ratio of 0.48 (0.29/
0.61) showed HSP27 was down-regulated in glioma tissues.
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Leu-d3 labeling
Human glioma cell line H4 was cultured in isotope-label-
ing 1640 media with 10% dialyzed fetal bovine serum
(FBS, GIBCO), which was supplemented with the Leu-d3
(L-leucine-5,5,5-D3, 98%; Cambridge Isotope Labora-
tories, Inc, U.K.) replaced normal Leu-d0. The labeling
H4 cells were cultured at 37°C with 5% CO2,a n dg r o w n
at least for five passages until complete labeling for pro-
tein identification and quantification. The culture media
were changed every 3 days, and cell pellets were respec-
tively collected for every cell passage to monitor the
labeling ratio like as our previous reports [26,29,30].
Tissues
HGTs and PBTs were obtained from West China Hos-
pital, Sichuan University of China with the offers’
informed consent. Each sample was identified through
pathologic biopsy. PBTs, which show typical characteri-
zation of normal brain tissues, are taken as the normal
brain tissues. The glioma tissues used in our studies
were identified as the astrocytoma with a grade II. All
tissues were gained immediately after surgical operation,
and stored in the liquid nitrogen. The study was
approved by the local institutional ethics committee.
Antibodies
HSP27 monoclonal antibody was purchased from Cell
Signaling Technology, Inc. (G31, #2402, Cell Signaling
Technology, Inc., USA). The b-actin antibody (sc-1616,
Santa Cruz, USA) was taken as a control for western
blot. The secondary antibodies were purchased from
Abcam (Abcam inc., USA).
Protein extraction
Different passages of H4 cells were collected, cell pellets
and tissue samples were respectively treated to extract
total proteins by our previous method [26]. The protein
concentration was quantified using the Protein Assay
Kit (#500-0006, Bio-Rad, USA).
Figure 4 The expression validation of HSP27 in glioma tissues by RT-PCR (A) and Western blot (B). HGTs: human glioma tissues;
PBTs: para-cancerous brain tissues. Marker: DNA Marker; The b-actin was taken as a loading control.
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Page 7 of 12Figure 5 The expression and distribution of HSP27 in human glioma and para-cancerous brain tissues. (A) the HE staining of para-
cancerous brain tissues, which have typical characterization of normal brain tissues; (B) HE staining of glioma tissues. HSP27 immunoreactivity in
the representative para-cancerous brain tissue (C) and glioma tissue (D) (original magnification ×400). The positive staining of HSP27 in the
neuronal somata and proximal processes was shown as yellow-brown granules indicated by arrows. The figure c2-d2 was the insert of its
corresponding expanded figure c1-d1. The scale bar was 10 μm.
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In order to detect the labeling efficiency of H4 cells,
proteins were separated by SDS-PAGE and stained with
Coomassie blue (R-250, Bio-Rad, USA). The band of b-
actin was excised, subjected to in-gel tryptic digestion.
The peptides were resolved in 50% acetonitrile/0.1% tri-
fluoroacetic acid and analyzed by the electrospray ioni-
zation-time of flight (ESI-TOF) mass spectrometry with
reverse liquid chromatography (LC) (Waters Corpora-
tion, USA).
To identify and quantify HSP expression profiles in
two different states of brain tissues by the SILAC-MS
technique, 20 μgp r o t e i n sf r o mL e u - d 3-labeling H4 cells
were respectively mixed with same quantity of proteins
from HGTs and PBTs, then the protein mixture was
separated on 12% SDS-PAGE and stained by Coomassie
blue (R-250). Gels were excised and subjected to in-gel
digestion by MS-grade trypsin (#V5113, Promega, USA),
peptides were identified by LC-MS/MS mainly as
described as following.
Protein identification and quantification by LC-MS/MS
Protein identification was performed by LC-nanospray-
MS/MS analysis using a QSTAR XL mass spectrometer
(Applied Biosystems, USA). The MASCOT server was
used to interpret the LC-MS/MS data by searching
against human proteins from EMBL-EBI database (IPI-
human-335). The parameters of database search had
been described before [26,27].
The expression level of a specific heat shock protein
was quantified by tracking its unique pairs of Leu-con-
taining peptides from mass spectra. The SILAC ratio of
one protein was defined as the relative intensity ratio of
Leu-d0-containing peptides from each kind of tissues
versus that of Leu-d3-labeling peptides from H4 cells,
and it was averaged when several peptides were used for
quantification for one protein. The SILAC ratio1 was
represented the ratio of isotope peaks from the protein
mixture of HGTs with labeled H4 cells (HGTs/H4
cells), and the SILAC ratio2 was the ratio of isotope
peaks from the protein mixture of PBTs with labeled
H4 cells (PBTs/H4 cells). Therefore, the relative expres-
sion levels (change ratio) of HSPs in HGTs versus PBTs
were estimated by calculating the ratio of their SILAC
ratios (SILAC ratio1/SILAC ratio2).
Semiquantitative RT-PCR
Total RNA was isolated using Trizol reagent (Invitro-
gen) to take as template to amplify each target cDNA
fragment. The primers of HSP27 and b-actin for RT-
PCR were designed as following. The forward primer for
HSP27 was 5’-TCC CTG GAT GTC AAC CAC TTC
Figure 6 The expression variation of HSP27 protein under heat shock (A). The relative strength of band was determined based on the
control by Quality-One software(Bio-Rad) (B). Compared with the control, HSP27 expression was increased to 3.83 and 5.36-fold at time point of
30 min and 1 h after heat shock, then gradually jumped back near to the background level at 2 h and 3 h, with 2.3 and 1.12-fold expression
versus the control. CON: the control cells without heat shock.
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AGG AGG AAA CTT G-3’ (22 bp), and the length of
the amplified cDNA was 184 bp. The designed primers
for b-actin was 5’-CGG GAA ATC GTG CGT GAC-
3’(18 bp, forward), 5’-TGG AAG GTG GAC AGC GAG
G-3’ (19 bp, reverse), and the length of the amplified
cDNA was 434 bp.
The PCR reaction was performed in 25 μl system,
which contained 2.5 μl PCR- buffer, 1.5 μlM g C l 2,2μl
dNTPs, 1 μl of 10 pmol forward and reverse primer, 2
μl cDNA template synthesized by using the RevertAid™
First Strand cDNA Synthesis Kit (#K1622, Fermentas,
USA), 0.5 μl rTaq polymerase (Takara), and 11.5 μl
H2O. The reaction was performed as follows: first cycle
at 95°C for 2 min, and then 30 cycles at 94°C for 45 s,
54°C for 1 min, 72°C for 1 min and a final extension
cycle of 72°C for 5 min. 5 μlo fP C Rp r o d u c t sw e r e
identified by 1.2% agar electrophoresis, stained with
Goldview (Sigma, USA), and visualized by UV fluores-
cence. The house-keeping gene b-actin was taken as a
loading control.
Western blotting and immunohistochemistry
Each of 30 μg protein from the tissues (HGTs and
PBTs) or treated cells was separated on 12% SDS-PAGE
and transferred to PVDF membrane to incubate with
Figure 7 The survival rate of H4 cells with heat shock. It was noticed that cell proliferation ability under heat shock at the time point of
30 min (OD595 nm, 0.57 ± 0.03, n = 18) was almost similar with that at 1 h (OD595 nm, 0.57 ± 0.04, n = 18), and a same status was observed at
the time point of 2 h (OD595 nm, 0.48 ± 0.03, n = 18) and 3 h (OD595 nm, 0.47 ± 0.03, n = 18) treatment. However, at the time point of 0.5-1 h
and 2-3 h treatment, compared with control (OD595 nm, 0.63 ± 0.05, n = 18), cell growth had significantly decreased (p < 0.01) in these two
groups. CON: the control cells without heat shock.
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and the b-actin was taken as the loading control.
The paraffin-embedded PBTs and HGTs were cut into
slices with 4 μm thickness for Hematoxylin-Eosin (HE)
and IHC analysis. The autologous para-cancerous brain
t i s s u e sw e r eu s e df o rt h ep o s i t i v ec o n t r o lo fH S P 2 7
expression. The primary HSP27 antibodies, 1:500 diluted
in PBS, was applied for IHC.
Heat shock treatment on H4 cells
Human glioma H4 cells were cultured in media 1640
with 10% FBS. After cells grew to 70% confluence, the
media were carefully removed. Cells were washed gently
with sterile PBS and then overlaid with pre-warmed
(43°C) media. Cells were incubated in an incubator with
43°C for 0 min, 30 min, 1 h, 2 h and 3 h respectively.
After cells were treated by heat shock, the old media
were replaced with the new, and cells were incubated in
37°C for another 24 h to collect for western blotting. The
H4 cells without heat shock were used as the control.
Effects of heat shock on cell growth
H4 cells were seeded into 96-well plates at a density of
3-4 × 10
3/well. When cell confluence was about 70%,
cells were washed gently with sterile PBS and then over-
laid with pre-warmed (43°C) media. Cells were treated
by heat shock at 43°C respectively for 0 min, 30 min, 1 h,
2 h and 3 h described as above, then were incubated for
24 h at 37°C, and 20 μl of MTT (5 mg/ml in PBS)
(Sigma) was added to incubate for another 4 h. The med-
ium was removed, and 200 μl DMSO was added to
dissolve MTT precipitate. After agitating cells on orbital
shaker for 10 min, the absorbance was detected on a
spectra max MS (MDC, USA) at 595 nm with a reference
filter at 630 nm. The H4 cells without heat shock were
used as the control.
Data statistical analysis
All quantitative data were calculated as mean ± SD from
at least two repeated biological experiments. Comparisons
between two groups were performed by Student’stt e s t ,
comparisons among multiple groups were performed by
One-way ANOVA and Dunnet-t test. The statistical sig-
nificance was defined as P < 0.05. Computations were
determined by the SPSS 11.5 software package.
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